Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

Trigeminal Neuropathic Pain Clinical Trial

Official title:

Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03003715
• Other study ID #: HUM00024607
• Status: Completed
• Phase: N/A
• First received: December 22, 2016
• Last updated: November 21, 2017
• Start date: September 2011
• Est. completion date: December 2012

Study information

• Verified date: November 2017
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this study to integrate techniques producing images of the brain (also called neuroimaging techniques) with non-invasive brain stimulation to investigate factors that may be associated with chronic pain in patients with Trigeminal Neuropathic Pain (TNP).

Description:

Trigeminal neuropathic pain (TNP) disorders, such as classical trigeminal and post-surgical neuralgia, are debilitating chronic conditions with pain that is either spontaneous or that can be intensely evoked by light touch to the facial skin. Although neuroimaging techniques have provided insights into some brain mechanisms of experimental trigeminal pain in humans (DaSilva et al., 2002; Borsook et al., 2003), it is not well understood how structural and molecular mechanisms are affected during the course of TNP, and how they can be safely modulated for therapeutic and research purposes. Understanding these processes is crucial to determine the structures engaged in the development and persistence of TNP.

We will test the hypothesis that chronicity of TNP is sustained by changes at cellular and molecular levels in neural circuits associated with pain perception and modulation, rather than by the initial peripheral etiology, and that this dysfunction can be safely targeted and modulated as a therapeutic approach by transcranial direct current stimulation (tDCS). To achieve this goal we will use a neuroimaging technique, PET, employing a mathematical model that permits the quantification of opioid receptor availability in vivo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Patient Inclusion Criteria:

• Daily chronic TNP for at least 6 months not adequately controlled by pervious medicine therapies;

• minimal average baseline pain score of 4 (moderate to severe) in the visual analogue scale (VAS);

• unilateral pain

• orofacial allodynic region to mechanical (light touch or palpation) or thermal stimulation (head or cold);

Patient Exclusion Criteria:

• pregnancy or planning to become pregnant

• local pathology (e.g. orofacial lesion)

• history of systemic disorders (e.g. MS)

• history of other chronic pain disorder (e.g. back pain)

• recent orofacial surgery or trauma (< 6 months)

• history of central origin disorders (e.g. stroke)

Related Conditions & MeSH terms

• Neuralgia
• Trigeminal Neuropathic Pain

Intervention

Procedure:
• PET Scans
Two 90 minute scans whose maximum radiological dose is 15 mCi [11 C] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
• transcranial direct current stimulation (tDCS)
In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
• MRI
No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.

Other:
• sham tDCS (prior to real tDCS)
For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in MOR BPND levels	change from baseline to versus sham or active tDCS	place weeks after not more than 6months